Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

医学 经皮冠状动脉介入治疗 荟萃分析 传统PCI 内科学 观察研究 心肌梗塞 冲程(发动机) 不利影响 随机对照试验 心脏病学 机械工程 工程类
作者
Mattía Galli,Stefano Benenati,Davide Capodanno,Francesco Franchi,Fabiana Rollini,Domenico D’Amario,Italo Porto,Dominick J. Angiolillo
出处
期刊:The Lancet [Elsevier]
卷期号:397 (10283): 1470-1483 被引量:176
标识
DOI:10.1016/s0140-6736(21)00533-x
摘要

Summary

Background

Whether guided selection of antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) is effective in improving outcomes compared with standard antiplatelet therapy remains controversial. We assessed the safety and efficacy of guided versus standard selection of antiplatelet therapy in patients undergoing PCI.

Methods

For this systematic review and meta-analysis, from Aug 20 to Oct 25, 2020, we searched MEDLINE (via PubMed), Cochrane, Embase, and Web of Science databases for randomised controlled trials and observational studies published in any language that compared guided antiplatelet therapy, by means of platelet function testing or genetic testing, versus standard antiplatelet therapy in patients undergoing PCI. Two reviewers independently assessed study eligibility, extracted the data, and assessed risk of bias. Risk ratios (RRs) and 95% CIs were used with random-effects or fixed-effect models according to the estimated heterogeneity among studies assessed by the I2 index. Coprimary endpoints were trial-defined primary major adverse cardiovascular events and any bleeding. Key secondary endpoints were all-cause death, cardiovascular death, myocardial infarction, stroke, definite or probable stent thrombosis, and major and minor bleeding. This study is registered with PROSPERO (CRD42021215901).

Findings

3656 potentially relevant articles were screened. Our analysis included 11 randomised controlled trials and three observational studies with data for 20 743 patients. Compared with standard therapy, guided selection of antiplatelet therapy was associated with a reduction in major adverse cardiovascular events (RR 0·78, 95% CI 0·63–0·95, p=0·015) and reduced bleeding, although not statistically significant (RR 0·88, 0·77–1·01, p=0·069). Cardiovascular death (RR 0·77, 95% CI 0·59–1·00, p=0·049), myocardial infarction (RR 0·76, 0·60–0·96, p=0·021), stent thrombosis (RR 0·64, 0·46–0·89, p=0·011), stroke (RR 0·66, 0·48–0·91, p=0·010), and minor bleeding (RR 0·78, 0·67–0·92, p=0·0030) were reduced with guided therapy compared with standard therapy. Risks of all-cause death and major bleeding did not differ between guided and standard approaches. Outcomes varied according to the strategy used, with an escalation approach associated with a significant reduction in ischaemic events without any trade-off in safety, and a de-escalation approach associated with a significant reduction in bleeding, without any trade-off in efficacy.

Interpretation

Guided selection of antiplatelet therapy improved both composite and individual efficacy outcomes with a favourable safety profile, driven by a reduction in minor bleeding, supporting the use of platelet function or genetic testing to optimise the choice of agent in patients undergoing PCI.

Funding

None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
坚强丹雪完成签到,获得积分10
2秒前
4秒前
6秒前
WZ0904发布了新的文献求助10
8秒前
狂野静曼完成签到 ,获得积分10
9秒前
武映易完成签到 ,获得积分10
11秒前
zzz发布了新的文献求助10
12秒前
13秒前
大蒜味酸奶钊完成签到 ,获得积分10
13秒前
鱼宇纸完成签到 ,获得积分10
13秒前
LEE完成签到,获得积分20
13秒前
13秒前
Ava应助无限的绿真采纳,获得10
15秒前
小马甲应助xiongdi521采纳,获得10
15秒前
科研通AI5应助陶醉觅夏采纳,获得200
18秒前
憨鬼憨切发布了新的文献求助10
18秒前
18秒前
宇宙暴龙战士暴打魔法少女完成签到,获得积分10
20秒前
21秒前
22秒前
hh应助科研通管家采纳,获得10
22秒前
科研通AI5应助科研通管家采纳,获得10
22秒前
Ava应助科研通管家采纳,获得10
22秒前
Eva完成签到,获得积分10
22秒前
传奇3应助科研通管家采纳,获得10
22秒前
斯文败类应助科研通管家采纳,获得10
22秒前
爆米花应助科研通管家采纳,获得10
23秒前
科研通AI5应助科研通管家采纳,获得10
23秒前
搜集达人应助科研通管家采纳,获得10
23秒前
思源应助科研通管家采纳,获得10
23秒前
汉堡包应助科研通管家采纳,获得10
23秒前
清爽老九应助科研通管家采纳,获得20
23秒前
传奇3应助科研通管家采纳,获得10
23秒前
greenPASS666发布了新的文献求助10
23秒前
涂欣桐应助科研通管家采纳,获得10
23秒前
英俊的铭应助科研通管家采纳,获得10
23秒前
secbox完成签到,获得积分10
24秒前
刘哈哈发布了新的文献求助30
24秒前
xyzdmmm完成签到,获得积分10
25秒前
25秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527998
求助须知:如何正确求助?哪些是违规求助? 3108225
关于积分的说明 9288086
捐赠科研通 2805889
什么是DOI,文献DOI怎么找? 1540195
邀请新用户注册赠送积分活动 716950
科研通“疑难数据库(出版商)”最低求助积分说明 709849